Reviews - 1osv mentioned but not cited (4)
- An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. Yang K, Köck K, Sedykh A, Tropsha A, Brouwer KL. J Pharm Sci 102 3037-3057 (2013)
- Farnesoid X receptor (FXR): Structures and ligands. Jiang L, Zhang H, Xiao D, Wei H, Chen Y. Comput Struct Biotechnol J 19 2148-2159 (2021)
- FXR: structures, biology, and drug development for NASH and fibrosis diseases. Tian SY, Chen SM, Pan CX, Li Y. Acta Pharmacol Sin 43 1120-1132 (2022)
- Natural Products Targeting Liver X Receptors or Farnesoid X Receptor. She J, Gu T, Pang X, Liu Y, Tang L, Zhou X. Front Pharmacol 12 772435 (2021)
Articles - 1osv mentioned but not cited (26)
- A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity. Kim DH, Xiao Z, Kwon S, Sun X, Ryerson D, Tkac D, Ma P, Wu SY, Chiang CM, Zhou E, Xu HE, Palvimo JJ, Chen LF, Kemper B, Kemper JK. EMBO J 34 184-199 (2015)
- Evolution of the bile salt nuclear receptor FXR in vertebrates. Reschly EJ, Ai N, Ekins S, Welsh WJ, Hagey LR, Hofmann AF, Krasowski MD. J Lipid Res 49 1577-1587 (2008)
- Protein-ligand binding with the coarse-grained Martini model. Souza PCT, Thallmair S, Conflitti P, Ramírez-Palacios C, Alessandri R, Raniolo S, Limongelli V, Marrink SJ. Nat Commun 11 3714 (2020)
- Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation. Soisson SM, Parthasarathy G, Adams AD, Sahoo S, Sitlani A, Sparrow C, Cui J, Becker JW. Proc Natl Acad Sci U S A 105 5337-5342 (2008)
- Performance of HADDOCK and a simple contact-based protein-ligand binding affinity predictor in the D3R Grand Challenge 2. Kurkcuoglu Z, Koukos PI, Citro N, Trellet ME, Rodrigues JPGLM, Moreira IS, Roel-Touris J, Melquiond ASJ, Geng C, Schaarschmidt J, Xue LC, Vangone A, Bonvin AMJJ. J Comput Aided Mol Des 32 175-185 (2018)
- Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. Renga B, Mencarelli A, D'Amore C, Cipriani S, D'Auria MV, Sepe V, Chini MG, Monti MC, Bifulco G, Zampella A, Fiorucci S. PLoS One 7 e30443 (2012)
- Molecular tuning of farnesoid X receptor partial agonism. Merk D, Sreeramulu S, Kudlinzki D, Saxena K, Linhard V, Gande SL, Hiller F, Lamers C, Nilsson E, Aagaard A, Wissler L, Dekker N, Bamberg K, Schubert-Zsilavecz M, Schwalbe H. Nat Commun 10 2915 (2019)
- Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum. Grienke U, Mihály-Bison J, Schuster D, Afonyushkin T, Binder M, Guan SH, Cheng CR, Wolber G, Stuppner H, Guo DA, Bochkov VN, Rollinger JM. Bioorg Med Chem 19 6779-6791 (2011)
- The evolution of farnesoid X, vitamin D, and pregnane X receptors: insights from the green-spotted pufferfish (Tetraodon nigriviridis) and other non-mammalian species. Krasowski MD, Ai N, Hagey LR, Kollitz EM, Kullman SW, Reschly EJ, Ekins S. BMC Biochem 12 5 (2011)
- Conformational modulation of the farnesoid X receptor by prenylflavonoids: Insights from hydrogen deuterium exchange mass spectrometry (HDX-MS), fluorescence titration and molecular docking studies. Yang L, Broderick D, Campbell Y, Gombart AF, Stevens JF, Jiang Y, Hsu VL, Bisson WH, Maier CS. Biochim Biophys Acta 1864 1667-1677 (2016)
- The glucocorticoid mometasone furoate is a novel FXR ligand that decreases inflammatory but not metabolic gene expression. Bijsmans IT, Guercini C, Ramos Pittol JM, Omta W, Milona A, Lelieveld D, Egan DA, Pellicciari R, Gioiello A, van Mil SW. Sci Rep 5 14086 (2015)
- Conformational dynamics of human FXR-LBD ligand interactions studied by hydrogen/deuterium exchange mass spectrometry: insights into the antagonism of the hypolipidemic agent Z-guggulsterone. Yang L, Broderick D, Jiang Y, Hsu V, Maier CS. Biochim Biophys Acta 1844 1684-1693 (2014)
- Preliminary structure-activity relationship on theonellasterol, a new chemotype of FXR antagonist, from the marine sponge Theonella swinhoei. Sepe V, Ummarino R, D'Auria MV, Taglialatela-Scafati O, Marino SD, D'Amore C, Renga B, Chini MG, Bifulco G, Nakao Y, Fusetani N, Fiorucci S, Zampella A. Mar Drugs 10 2448-2466 (2012)
- Structure-based drug design targeting the cell membrane receptor GPBAR1: exploiting the bile acid scaffold towards selective agonism. Di Leva FS, Festa C, Renga B, Sepe V, Novellino E, Fiorucci S, Zampella A, Limongelli V. Sci Rep 5 16605 (2015)
- Two farnesoid X receptor alpha isoforms in Japanese medaka (Oryzias latipes) are differentially activated in vitro. Howarth DL, Hagey LR, Law SHW, Ai N, Krasowski MD, Ekins S, Moore JT, Kollitz EM, Hinton DE, Kullman SW. Aquat Toxicol 98 245-255 (2010)
- Optimal affinity ranking for automated virtual screening validated in prospective D3R grand challenges. Wingert BM, Oerlemans R, Camacho CJ. J Comput Aided Mol Des 32 287-297 (2018)
- Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases. Festa C, De Marino S, Carino A, Sepe V, Marchianò S, Cipriani S, Di Leva FS, Limongelli V, Monti MC, Capolupo A, Distrutti E, Fiorucci S, Zampella A. Front Pharmacol 8 162 (2017)
- Discovery of Natural Products as Novel and Potent FXR Antagonists by Virtual Screening. Diao Y, Jiang J, Zhang S, Li S, Shan L, Huang J, Zhang W, Li H. Front Chem 6 140 (2018)
- Conformational Characterization of the Co-Activator Binding Site Revealed the Mechanism to Achieve the Bioactive State of FXR. Kumari A, Mittal L, Srivastava M, Pathak DP, Asthana S. Front Mol Biosci 8 658312 (2021)
- Discovery of new FXR agonists based on 6-ECDCA binding properties by virtual screening and molecular docking. Giancristofaro A, Barbosa AJM, Ammazzalorso A, Amoia P, De Filippis B, Fantacuzzi M, Giampietro L, Maccallini C, Amoroso R. Medchemcomm 9 1630-1638 (2018)
- Natural Product 2-Oxokolavenol Is a Novel FXR Agonist. Guo F, Gao Y, Li X, Lei X. Molecules 27 8968 (2022)
- Studies on the Importance of the 7α-, and 12α- hydroxyl groups of N-Aryl-3α,7α,12α-trihydroxy-5β-cholan-24-amides on their Antigermination Activity Against a Hypervirulent Strain of Clostridioides (Clostridium) difficile. Sharma SK, Yip C, Simon MP, Phan J, Abel-Santos E, Firestine SM. Bioorg Med Chem 52 116503 (2021)
- Dissecting the allosteric FXR modulation: a chemical biology approach using guggulsterone as a chemical tool. Passeri D, Carotti A, Pittol JMR, Ciaccioli G, Pellicciari R, van Mil SWC, Gioiello A. Medchemcomm 10 1412-1419 (2019)
- Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome. Gay MD, Cao H, Shivapurkar N, Dakshanamurthy S, Kallakury B, Tucker RD, Kwagyan J, Smith JP. Int J Mol Sci 23 1899 (2022)
- Biomimetic Total Synthesis and the Biological Evaluation of Natural Product (-)-Fargesone A as a Novel FXR Agonist. Guo F, Chen K, Dong H, Hu D, Gao Y, Liu C, Laphookhieo S, Lei X. JACS Au 2 2830-2838 (2022)
- Introduction of Nonacidic Side Chains on 6-Ethylcholane Scaffolds in the Identification of Potent Bile Acid Receptor Agonists with Improved Pharmacokinetic Properties. Finamore C, Baronissi G, Marchianò S, Di Leva FS, Carino A, Monti MC, Limongelli V, Zampella A, Fiorucci S, Sepe V. Molecules 24 E1043 (2019)
Reviews citing this publication (42)
- Role of bile acids and bile acid receptors in metabolic regulation. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Physiol Rev 89 147-191 (2009)
- Targeting bile-acid signalling for metabolic diseases. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Nat Rev Drug Discov 7 678-693 (2008)
- The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Claudel T, Staels B, Kuipers F. Arterioscler Thromb Vasc Biol 25 2020-2030 (2005)
- Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Huang P, Chandra V, Rastinejad F. Annu Rev Physiol 72 247-272 (2010)
- FXR: a metabolic regulator and cell protector. Wang YD, Chen WD, Moore DD, Huang W. Cell Res 18 1087-1095 (2008)
- Bile salts of vertebrates: structural variation and possible evolutionary significance. Hofmann AF, Hagey LR, Krasowski MD. J Lipid Res 51 226-246 (2010)
- Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. Porez G, Prawitt J, Gross B, Staels B. J Lipid Res 53 1723-1737 (2012)
- Deciphering the nuclear bile acid receptor FXR paradigm. Modica S, Gadaleta RM, Moschetta A. Nucl Recept Signal 8 e005 (2010)
- The nuclear receptor superfamily: A structural perspective. Weikum ER, Liu X, Ortlund EA. Protein Sci 27 1876-1892 (2018)
- Ligand control of coregulator recruitment to nuclear receptors. Nettles KW, Greene GL. Annu Rev Physiol 67 309-333 (2005)
- International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Moore DD, Kato S, Xie W, Mangelsdorf DJ, Schmidt DR, Xiao R, Kliewer SA. Pharmacol Rev 58 742-759 (2006)
- Guts and Gall: Bile Acids in Regulation of Intestinal Epithelial Function in Health and Disease. Hegyi P, Maléth J, Walters JR, Hofmann AF, Keely SJ. Physiol Rev 98 1983-2023 (2018)
- Understanding nuclear receptor form and function using structural biology. Rastinejad F, Huang P, Chandra V, Khorasanizadeh S. J Mol Endocrinol 51 T1-T21 (2013)
- Retinoic acid actions through mammalian nuclear receptors. Huang P, Chandra V, Rastinejad F. Chem Rev 114 233-254 (2014)
- Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and post-translational modifications. Kemper JK. Biochim Biophys Acta 1812 842-850 (2011)
- Transport and biological activities of bile acids. Zwicker BL, Agellon LB. Int J Biochem Cell Biol 45 1389-1398 (2013)
- Regulation of drug and bile salt transporters in liver and intestine. Kullak-Ublick GA, Becker MB. Drug Metab Rev 35 305-317 (2003)
- Peroxisomes and bile acid biosynthesis. Ferdinandusse S, Houten SM. Biochim Biophys Acta 1763 1427-1440 (2006)
- Orphan nuclear receptors adopted by crystallography. Ingraham HA, Redinbo MR. Curr Opin Struct Biol 15 708-715 (2005)
- The Farnesoid X Receptor (FXR) as modulator of bile acid metabolism. Kuipers F, Claudel T, Sturm E, Staels B. Rev Endocr Metab Disord 5 319-326 (2004)
- Nuclear receptor control of enterohepatic circulation. Gonzalez FJ. Compr Physiol 2 2811-2828 (2012)
- Nuclear bile acid signaling through the farnesoid X receptor. Mazuy C, Helleboid A, Staels B, Lefebvre P. Cell Mol Life Sci 72 1631-1650 (2015)
- Structural and functional insights into nuclear receptor signaling. Jin L, Li Y. Adv Drug Deliv Rev 62 1218-1226 (2010)
- Role of farnesoid X receptor in inflammation and resolution. Shaik FB, Prasad DV, Narala VR. Inflamm Res 64 9-20 (2015)
- The enterohepatic nuclear receptors are major regulators of the enterohepatic circulation of bile salts. Houten SM, Auwerx J. Ann Med 36 482-491 (2004)
- Orphan nuclear receptors as targets for drug development. Mukherjee S, Mani S. Pharm Res 27 1439-1468 (2010)
- O-GlcNAcylation Links ChREBP and FXR to Glucose-Sensing. Benhamed F, Filhoulaud G, Caron S, Lefebvre P, Staels B, Postic C. Front Endocrinol (Lausanne) 5 230 (2014)
- Saponins as modulators of nuclear receptors. Zhang T, Zhong S, Li T, Zhang J. Crit Rev Food Sci Nutr 60 94-107 (2020)
- Recent advances in understanding noroviruses. Bartnicki E, Cunha JB, Kolawole AO, Wobus CE. F1000Res 6 79 (2017)
- The potential role of in silico approaches to identify novel bioactive molecules from natural resources. Olğaç A, Orhan IE, Banoglu E. Future Med Chem 9 1665-1686 (2017)
- Molecular Basis of Bile Acid-FXR-FGF15/19 Signaling Axis. Katafuchi T, Makishima M. Int J Mol Sci 23 6046 (2022)
- Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application. Sepe V, Distrutti E, Limongelli V, Fiorucci S, Zampella A. Future Med Chem 7 1109-1135 (2015)
- Nuclear receptor ligands and cofactor recruitment: is there a coactivator "on deck"? Nettles KW, Greene GL. Mol Cell 11 850-851 (2003)
- Farnesoid X receptor modulators (2011 - 2014): a patent review. Sepe V, Distrutti E, Fiorucci S, Zampella A. Expert Opin Ther Pat 25 885-896 (2015)
- Physiological and molecular responses to bariatric surgery: markers or mechanisms underlying T2DM resolution? Hutch CR, Sandoval DA. Ann N Y Acad Sci 1391 5-19 (2017)
- Post-Translational Modifications of FXR; Implications for Cholestasis and Obesity-Related Disorders. Appelman MD, van der Veen SW, van Mil SWC. Front Endocrinol (Lausanne) 12 729828 (2021)
- Beyond the human genome: examples of nuclear receptor analysis in model organisms and potential for drug discovery. Maglich JM, Sluder AE, Willson TM, Moore JT. Am J Pharmacogenomics 3 345-353 (2003)
- Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism. Zhou W, Anakk S. Mol Cell Endocrinol 549 111616 (2022)
- Colon cancer checks in when bile acids check out: the bile acid-nuclear receptor axis in colon cancer. Tang Q, Evans RM. Essays Biochem 65 1015-1024 (2021)
- The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity. Rausch M, Samodelov SL, Visentin M, Kullak-Ublick GA. Int J Mol Sci 23 13967 (2022)
- Some molecular targets for antihyperlipidemic drug research. Arya N, Kharjul MD, Shishoo CJ, Thakare VN, Jain KS. Eur J Med Chem 85 535-568 (2014)
- International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023. Burris TP, de Vera IMS, Cote I, Flaveny CA, Wanninayake US, Chatterjee A, Walker JK, Steinauer N, Zhang J, Coons LA, Korach KS, Cain DW, Hollenberg AN, Webb P, Forrest D, Jetten AM, Edwards DP, Grimm SL, Hartig S, Lange CA, Richer JK, Sartorius CA, Tetel M, Billon C, Elgendy B, Hegazy L, Griffett K, Peinetti N, Burnstein KL, Hughes TS, Sitaula S, Stayrook KR, Culver A, Murray MH, Finck BN, Cidlowski JA. Pharmacol Rev 75 1233-1318 (2023)
Articles citing this publication (78)
- Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall HU, Bamberg K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F. Cell Metab 17 225-235 (2013)
- The bile acid receptor FXR is a modulator of intestinal innate immunity. Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S. J Immunol 183 6251-6261 (2009)
- The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, Riccardi L, Orlandi S, Pellicciari R, Morelli A. Gastroenterology 127 1497-1512 (2004)
- Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. Sorg JA, Sonenshein AL. J Bacteriol 192 4983-4990 (2010)
- Identification of COUP-TFII orphan nuclear receptor as a retinoic acid-activated receptor. Kruse SW, Suino-Powell K, Zhou XE, Kretschman JE, Reynolds R, Vonrhein C, Xu Y, Wang L, Tsai SY, Tsai MJ, Xu HE. PLoS Biol 6 e227 (2008)
- Target flexibility: an emerging consideration in drug discovery and design. Cozzini P, Kellogg GE, Spyrakis F, Abraham DJ, Costantino G, Emerson A, Fanelli F, Gohlke H, Kuhn LA, Morris GM, Orozco M, Pertinhez TA, Rizzi M, Sotriffer CA. J Med Chem 51 6237-6255 (2008)
- A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, Orlandi S, Pruzanski M, Morelli A, Pellicciari R. J Pharmacol Exp Ther 314 584-595 (2005)
- Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, Morelli A, Pruzanski M, Pellicciari R. J Pharmacol Exp Ther 315 58-68 (2005)
- Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. Fiorucci S, Clerici C, Antonelli E, Orlandi S, Goodwin B, Sadeghpour BM, Sabatino G, Russo G, Castellani D, Willson TM, Pruzanski M, Pellicciari R, Morelli A. J Pharmacol Exp Ther 313 604-612 (2005)
- The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism. Jin L, Feng X, Rong H, Pan Z, Inaba Y, Qiu L, Zheng W, Lin S, Wang R, Wang Z, Wang S, Liu H, Li S, Xie W, Li Y. Nat Commun 4 1937 (2013)
- Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative. Adachi R, Honma Y, Masuno H, Kawana K, Shimomura I, Yamada S, Makishima M. J Lipid Res 46 46-57 (2005)
- Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. Trottier J, Verreault M, Grepper S, Monté D, Bélanger J, Kaeding J, Caron P, Inaba TT, Barbier O. Hepatology 44 1158-1170 (2006)
- Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR. Krasowski MD, Ni A, Hagey LR, Ekins S. Mol Cell Endocrinol 334 39-48 (2011)
- Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064. Akwabi-Ameyaw A, Bass JY, Caldwell RD, Caravella JA, Chen L, Creech KL, Deaton DN, Jones SA, Kaldor I, Liu Y, Madauss KP, Marr HB, McFadyen RB, Miller AB, Navas F, Parks DJ, Spearing PK, Todd D, Williams SP, Wisely GB. Bioorg Med Chem Lett 18 4339-4343 (2008)
- The X-ray structure of a hemipteran ecdysone receptor ligand-binding domain: comparison with a lepidopteran ecdysone receptor ligand-binding domain and implications for insecticide design. Carmichael JA, Lawrence MC, Graham LD, Pilling PA, Epa VC, Noyce L, Lovrecz G, Winkler DA, Pawlak-Skrzecz A, Eaton RE, Hannan GN, Hill RJ. J Biol Chem 280 22258-22269 (2005)
- Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. Zhang JH, Nolan JD, Kennie SL, Johnston IM, Dew T, Dixon PH, Williamson C, Walters JR. Am J Physiol Gastrointest Liver Physiol 304 G940-8 (2013)
- Molecular and functional comparison of 1,25-dihydroxyvitamin D(3) and the novel vitamin D receptor ligand, lithocholic acid, in activating transcription of cytochrome P450 3A4. Jurutka PW, Thompson PD, Whitfield GK, Eichhorst KR, Hall N, Dominguez CE, Hsieh JC, Haussler CA, Haussler MR. J Cell Biochem 94 917-943 (2005)
- The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor. Frankenberg T, Miloh T, Chen FY, Ananthanarayanan M, Sun AQ, Balasubramaniyan N, Arias I, Setchell KD, Suchy FJ, Shneider BL. Hepatology 48 1896-1905 (2008)
- The nuclear hormone receptor farnesoid X receptor (FXR) is activated by androsterone. Wang S, Lai K, Moy FJ, Bhat A, Hartman HB, Evans MJ. Endocrinology 147 4025-4033 (2006)
- Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition. Vaquero J, Monte MJ, Dominguez M, Muntané J, Marin JJ. Biochem Pharmacol 86 926-939 (2013)
- The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Rizzo G, Renga B, Antonelli E, Passeri D, Pellicciari R, Fiorucci S. Mol Pharmacol 68 551-558 (2005)
- Structure of the heterodimeric ecdysone receptor DNA-binding complex. Devarakonda S, Harp JM, Kim Y, Ozyhar A, Rastinejad F. EMBO J 22 5827-5840 (2003)
- Structure of human N-acylphosphatidylethanolamine-hydrolyzing phospholipase D: regulation of fatty acid ethanolamide biosynthesis by bile acids. Magotti P, Bauer I, Igarashi M, Babagoli M, Marotta R, Piomelli D, Garau G. Structure 23 598-604 (2015)
- Identification of intermediates in the bile acid synthetic pathway as ligands for the farnesoid X receptor. Nishimaki-Mogami T, Une M, Fujino T, Sato Y, Tamehiro N, Kawahara Y, Shudo K, Inoue K. J Lipid Res 45 1538-1545 (2004)
- Fifty years with bile acids and steroids in health and disease. Sjövall J. Lipids 39 703-722 (2004)
- Oxysterol 22(R)-hydroxycholesterol induces the expression of the bile salt export pump through nuclear receptor farsenoid X receptor but not liver X receptor. Deng R, Yang D, Yang J, Yan B. J Pharmacol Exp Ther 317 317-325 (2006)
- Structure-activity relationship of bile acids and bile acid analogs in regard to FXR activation. Fujino T, Une M, Imanaka T, Inoue K, Nishimaki-Mogami T. J Lipid Res 45 132-138 (2004)
- Theonellasterols and conicasterols from Theonella swinhoei. Novel marine natural ligands for human nuclear receptors. De Marino S, Ummarino R, D'Auria MV, Chini MG, Bifulco G, Renga B, D'Amore C, Fiorucci S, Debitus C, Zampella A. J Med Chem 54 3065-3075 (2011)
- Analysis of HSD3B7 knockout mice reveals that a 3alpha-hydroxyl stereochemistry is required for bile acid function. Shea HC, Head DD, Setchell KD, Russell DW. Proc Natl Acad Sci U S A 104 11526-11533 (2007)
- Structural Basis for Small Molecule NDB (N-Benzyl-N-(3-(tert-butyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino) Benzamide) as a Selective Antagonist of Farnesoid X Receptor α (FXRα) in Stabilizing the Homodimerization of the Receptor. Xu X, Xu X, Liu P, Zhu ZY, Chen J, Fu HA, Chen LL, Hu LH, Shen X. J Biol Chem 290 19888-19899 (2015)
- The farnesoid X receptor FXRalpha/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution. Cai SY, Xiong L, Wray CG, Ballatori N, Boyer JL. Am J Physiol Regul Integr Comp Physiol 293 R1400-9 (2007)
- A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis. Parafati M, Kirby RJ, Khorasanizadeh S, Rastinejad F, Malany S. Dis Model Mech 11 dmm033530 (2018)
- Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Hsu CW, Zhao J, Huang R, Hsieh JH, Hamm J, Chang X, Houck K, Xia M. Sci Rep 4 6437 (2014)
- Crystal structures of complexes of vitamin D receptor ligand-binding domain with lithocholic acid derivatives. Masuno H, Ikura T, Morizono D, Orita I, Yamada S, Shimizu M, Ito N. J Lipid Res 54 2206-2213 (2013)
- The hypolipidemic agent guggulsterone regulates the expression of human bile salt export pump: dominance of transactivation over farsenoid X receptor-mediated antagonism. Deng R, Yang D, Radke A, Yang J, Yan B. J Pharmacol Exp Ther 320 1153-1162 (2007)
- Cholestatic syndromes. Trauner M, Boyer JL. Curr Opin Gastroenterol 20 220-230 (2004)
- Hologram quantitative structure-activity relationships for a series of farnesoid X receptor activators. Honorio KM, Garratt RC, Andricopulo AD. Bioorg Med Chem Lett 15 3119-3125 (2005)
- Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists. Sepe V, Festa C, Renga B, Carino A, Cipriani S, Finamore C, Masullo D, Del Gaudio F, Monti MC, Fiorucci S, Zampella A. Sci Rep 6 19008 (2016)
- Structural conservation of ligand binding reveals a bile acid-like signaling pathway in nematodes. Zhi X, Zhou XE, Melcher K, Motola DL, Gelmedin V, Hawdon J, Kliewer SA, Mangelsdorf DJ, Xu HE. J Biol Chem 287 4894-4903 (2012)
- Fullerene sorting proteins. Calvaresi M, Zerbetto F. Nanoscale 3 2873-2881 (2011)
- Estrogen and Estrogen Receptor-α-Mediated Transrepression of Bile Salt Export Pump. Chen Y, Vasilenko A, Song X, Valanejad L, Verma R, You S, Yan B, Shiffka S, Hargreaves L, Nadolny C, Deng R. Mol Endocrinol 29 613-626 (2015)
- The novel compounds that activate farnesoid X receptor: the diversity of their effects on gene expression. Suzuki T, Tamehiro N, Sato Y, Kobayashi T, Ishii-Watabe A, Shinozaki Y, Nishimaki-Mogami T, Hashimoto T, Asakawa Y, Inoue K, Ohno Y, Yamaguchi T, Kawanishi T. J Pharmacol Sci 107 285-294 (2008)
- Towards the elucidation of molecular determinants of cooperativity in the liver bile acid binding protein. Pedò M, D'Onofrio M, Ferranti P, Molinari H, Assfalg M. Proteins 77 718-731 (2009)
- Inappropriate ileal conservation of bile acids in cholestatic liver disease: homeostasis gone awry. Hofmann AF. Gut 52 1239-1241 (2003)
- Identification of 15d-PGJ2 as an antagonist of farnesoid X receptor: molecular modeling with biological evaluation. Xu X, Lu Y, Chen L, Chen J, Luo X, Shen X. Steroids 78 813-822 (2013)
- Structure-activity relationship of bile alcohols as human farnesoid X receptor agonist. Iguchi Y, Kihira K, Nishimaki-Mogami T, Une M. Steroids 75 95-100 (2010)
- Autophagy-related intrinsically disordered proteins in intra-nuclear compartments. Na I, Meng F, Kurgan L, Uversky VN. Mol Biosyst 12 2798-2817 (2016)
- Reconstitution of functional nuclear receptor proteins using high pressure refolding. Schoner BE, Bramlett KS, Guo H, Burris TP. Mol Genet Metab 85 318-322 (2005)
- 5Alpha-bile alcohols function as farnesoid X receptor antagonists. Nishimaki-Mogami T, Kawahara Y, Tamehiro N, Yoshida T, Inoue K, Ohno Y, Nagao T, Une M. Biochem Biophys Res Commun 339 386-391 (2006)
- Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery. Yu DD, Lin W, Chen T, Forman BM. Bioorg Med Chem 21 4266-4278 (2013)
- Investigation around the Oxadiazole Core in the Discovery of a New Chemotype of Potent and Selective FXR Antagonists. Festa C, Finamore C, Marchianò S, Di Leva FS, Carino A, Monti MC, Del Gaudio F, Ceccacci S, Limongelli V, Zampella A, Fiorucci S, De Marino S. ACS Med Chem Lett 10 504-510 (2019)
- Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity. Elhaji YA, Stoica I, Dennis S, Purisima EO, Lumbroso R, Beitel LK, Trifiro MA. Hum Mol Genet 15 921-931 (2006)
- Using physics-based pose predictions and free energy perturbation calculations to predict binding poses and relative binding affinities for FXR ligands in the D3R Grand Challenge 2. Athanasiou C, Vasilakaki S, Dellis D, Cournia Z. J Comput Aided Mol Des 32 21-44 (2018)
- Asymmetric synthesis of the four diastereoisomers of a novel non-steroidal farnesoid X receptor (FXR) agonist: role of the chirality on the biological activity. Marinozzi M, Carotti A, Sardella R, Buonerba F, Ianni F, Natalini B, Passeri D, Rizzo G, Pellicciari R. Bioorg Med Chem 21 3780-3789 (2013)
- Identification of a lead pharmacophore for the development of potent nuclear receptor modulators as anticancer and X syndrome disease therapeutic agents. Lin HR, Abraham DJ. Bioorg Med Chem Lett 16 4178-4183 (2006)
- Incisterols, highly degraded marine sterols, are a new chemotype of PXR agonists. Chianese G, Sepe V, Limongelli V, Renga B, D'Amore C, Zampella A, Taglialatela-Scafati O, Fiorucci S. Steroids 83 80-85 (2014)
- Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD. Zhu Y, Xu S, Lu Y, Wei Y, Yao B, Guo F, Zheng X, Wang Y, He Y, Jin L, Li Y. Front Pharmacol 11 590 (2020)
- 3D-QSAR studies with the aid of molecular docking for a series of non-steroidal FXR agonists. Zhang T, Zhou JH, Shi LW, Zhu RX, Chen MB. Bioorg Med Chem Lett 17 2156-2160 (2007)
- 5beta-Cholane activators of the farnesol X receptor. Fukuchi J, Song C, Dai Q, Hiipakka RA, Liao S. J Steroid Biochem Mol Biol 94 311-318 (2005)
- Computational study of the binding mechanism between farnesoid X receptor α and antagonist N-benzyl-N-(3-(tertbutyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino) benzamide. Du J, Qiu M, Guo L, Yao X. J Biomol Struct Dyn 37 1628-1640 (2019)
- Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury. Sepe V, Marchianò S, Finamore C, Baronissi G, Di Leva FS, Carino A, Biagioli M, Fiorucci C, Cassiano C, Monti MC, Del Gaudio F, Novellino E, Limongelli V, Fiorucci S, Zampella A. ACS Med Chem Lett 10 407-412 (2019)
- Rational discovery of a novel interface for a coactivator in the peroxisome proliferator-activated receptor gamma: theoretical implications of impairment in type 2 diabetes mellitus. Shiraki T, Kodama TS, Jingami H, Kamiya N. Proteins 58 418-425 (2005)
- Cryptochinones from Cryptocarya chinensis act as farnesoid X receptor agonists. Lin HR, Chou TH, Huang DW, Chen IS. Bioorg Med Chem Lett 24 4181-4186 (2014)
- Letter Discovery of new non-steroidal farnesoid X receptor modulators through 3D shape similarity search and structure-based virtual screening. Wang L, Si P, Sheng Y, Chen Y, Wan P, Shen X, Tang Y, Chen L, Li W. Chem Biol Drug Des 85 481-487 (2015)
- Interfacial properties of most monofluorinated bile acids deviate markedly from the natural congeners: studies with the Langmuir-Pockels surface balance. Kauffman JM, Pellicciari R, Carey MC. J Lipid Res 46 571-581 (2005)
- Local motifs involved in the canonical structure of the ligand-binding domain in the nuclear receptor superfamily. Tsuji M. J Struct Biol 185 355-365 (2014)
- Synthesis and Biological Evaluation of a Series of Bile Acid Derivatives as FXR Agonists for Treatment of NASH. Xiao H, Li P, Li X, He H, Wang J, Guo F, Zhang J, Wei L, Zhang H, Shi Y, Hou L, Shen L, Chen Z, Du C, Fu S, Zhang P, Hao F, Wang P, Xu D, Liang W, Tian X, Zhang A, Cheng X, Yang L, Wang X, Zhang X, Li J, Chen S. ACS Med Chem Lett 8 1246-1251 (2017)
- Magnesium chenoursodeoxycholic acid ameliorates carbon tetrachloride-induced liver fibrosis in rats. Kang JW, Yoon SJ, Sung YK, Lee SM. Exp Biol Med (Maywood) 237 83-92 (2012)
- Workflows and performances in the ranking prediction of 2016 D3R Grand Challenge 2: lessons learned from a collaborative effort. Gao YD, Hu Y, Crespo A, Wang D, Armacost KA, Fells JI, Fradera X, Wang H, Wang H, Sherborne B, Verras A, Peng Z. J Comput Aided Mol Des 32 129-142 (2018)
- Discovery of Farnesoid X Receptor Antagonists Based on a Library of Oleanolic Acid 3-O-Esters through Diverse Substituent Design and Molecular Docking Methods. Wang SR, Xu T, Deng K, Wong CW, Liu J, Fang WS. Molecules 22 E690 (2017)
- Lepidozenolide from the liverwort Lepidozia fauriana acts as a farnesoid X receptor agonist. Lin HR. J Asian Nat Prod Res 17 149-158 (2015)
- Synthesis of Novel Farnesoid X Receptor Agonists and Validation of Their Efficacy in Activating Differentiation of Mouse Bone Marrow-Derived Mesenchymal Stem Cells into Osteoblasts. Fujimori K, Iguchi Y, Yamashita Y, Gohda K, Teno N. Molecules 24 E4155 (2019)
- Synthesis of atypical bile acids for use as investigative tools for the genetic defect of 3β-hydroxy-Δ(5)-C27-steroid oxidoreductase deficiency. Gioiello A, Cerra B, Zhang W, Vallerini GP, Costantino G, De Franco F, Passeri D, Pellicciari R, Setchell KD. J Steroid Biochem Mol Biol 144 Pt B 348-360 (2014)
- Molecular dynamics simulation study for LRH-1: interaction with fragments of SHP and function of phospholipid ligand. Zhang T, Zhou JH, Shi LW, Zhu RX, Chen MB. Proteins 70 1527-1539 (2008)
- The region of CQQQKPQRRP of PGC-1alpha interacts with the DNA-binding complex of FXR/RXRalpha. Kanaya E, Jingami H. Biochem Biophys Res Commun 342 734-743 (2006)
- Discovery of BMS-986318, a Potent Nonbile Acid FXR Agonist for the Treatment of Nonalcoholic Steatohepatitis. Carpenter J, Wu G, Wang Y, Cook EM, Wang T, Sitkoff D, Rossi KA, Mosure K, Zhuo X, Cao GG, Ziegler M, Azzara AV, Krupinski J, Soars MG, Ellsworth BA, Wacker DA. ACS Med Chem Lett 12 1413-1420 (2021)
- Gamma-Muricholic Acid Inhibits Nonalcoholic Steatohepatitis: Abolishment of Steatosis-Dependent Peroxidative Impairment by FXR/SHP/LXRα/FASN Signaling. Xie Y, Shen F, He Y, Guo C, Yang R, Cao H, Pan Q, Fan J. Nutrients 15 1255 (2023)
- Congress The jensen symposium; a tribute to a pioneer in the field of nuclear receptor biology. Glass CK, McDonnell DP. Mol Cell 13 459-467 (2004)